Your browser doesn't support javascript.
loading
Primary Human Hepatocyte Spheroid Model as a 3D In Vitro Platform for Metabolism Studies.
Kanebratt, Kajsa P; Janefeldt, Annika; Vilén, Liisa; Vildhede, Anna; Samuelsson, Kristin; Milton, Lucas; Björkbom, Anders; Persson, Marie; Leandersson, Carina; Andersson, Tommy B; Hilgendorf, Constanze.
Afiliación
  • Kanebratt KP; DMPK, Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden. Electronic address: kajsa.p.kanebratt@astrazeneca.com.
  • Janefeldt A; DMPK, Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden.
  • Vilén L; DMPK, Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden.
  • Vildhede A; DMPK, Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden.
  • Samuelsson K; DMPK, Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden.
  • Milton L; DMPK, Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden.
  • Björkbom A; DMPK, Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden.
  • Persson M; DMPK, Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden.
  • Leandersson C; Physical & Analytical Chemistry, Research and Early Development Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden.
  • Andersson TB; DMPK, Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden.
  • Hilgendorf C; DMPK, Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gothenburg, Sweden.
J Pharm Sci ; 110(1): 422-431, 2021 01.
Article en En | MEDLINE | ID: mdl-33122050
ABSTRACT
3D cultures of primary human hepatocytes (PHH) are emerging as a more in vivo-like culture system than previously available hepatic models. This work describes the characterisation of drug metabolism in 3D PHH spheroids. Spheroids were formed from three different donors of PHH and the expression and activities of important cytochrome P450 enzymes (CYP1A2, 2B6, 2C9, 2D6, and 3A4) were maintained for up to 21 days after seeding. The activity of CYP2B6 and 3A4 decreased, while the activity of CYP2C9 and 2D6 increased over time (P < 0.05). For six test compounds, that are metabolised by multiple enzymes, intrinsic clearance (CLint) values were comparable to standard in vitro hepatic models and successfully predicted in vivo CLint within 3-fold from observed values for low clearance compounds. Remarkably, the metabolic turnover of these low clearance compounds was reproducibly measured using only 1-3 spheroids, each composed of 2000 cells. Importantly, metabolites identified in the spheroid cultures reproduced the major metabolites observed in vivo, both primary and secondary metabolites were captured. In summary, the 3D PHH spheroid model shows promise to be used in drug discovery projects to study drug metabolism, including unknown mechanisms, over an extended period of time.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Hepatocitos / Sistema Enzimático del Citocromo P-450 Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Hepatocitos / Sistema Enzimático del Citocromo P-450 Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article